2021 年 38 巻 4 号 p. 539-543
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disorder of the CNS. Perception of cognitive functioning in patients with MS has increased exponentially over 30 years. Cognitive impairment might occur even in early course of MS, and it could become more frequent and moderate to severe in progressive course. Moreover, it may force a burden on patients with MS, their family members and society, due to the negative impact of workplace performance, daily life and social engagement. Cognitive functioning of MS could routinely be assessed by using some validated tools. A meta–analysis has highlighted that disease–modifying therapies exert positive effects on cognitive functioning in patients with MS. It is hoped that medical professions including neurologists or nurses, and social community would recognize the impact of cognition in patients with MS.
